micro-community-banner
  • Saved

1yr
New approaches to recovery after stroke

New approaches to recovery after stroke

Source : https://pubmed.ncbi.nlm.nih.gov/37697027/

After a stroke, several mechanisms of neural plasticity can be activated, which may lead to significant recovery. Rehabilitation therapies aim to restore surviving tissue over time and reorganize neural connections....

New rehabilitation technologies, including brain-computer interfaces, robot-assisted and virtual reality therapies, brain stimulation, and cell therapies, show promise in enhancing stroke recovery.

  • Saved

1yr
Exercise induces tissue-specific adaptations to enhance cardiometabolic health

Exercise induces tissue-specific adaptations to enhance cardiometabolic health

Source : https://pubmed.ncbi.nlm.nih.gov/38183980/

The risk associated with multiple cancers, cardiovascular disease, diabetes, and all-cause mortality is decreased in individuals who meet the current recommendations for physical activity. Therefore, regular exercise remains a cornerstone...

Regular exercise reduces the risk of multiple diseases and enhances cardiometabolic health through adaptations in various tissues, improving fitness, physical function, and glycemic control.

  • Saved

1yr
Major Advances in Diabetes Research and Treatment Unveiled at ADA Scientific Sessions

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, highlights key themes from this year’s ADA Scientific Sessions, including significant progress in obesity treatment, type 1 diabetes, technology, health disparities, and innovation. Notable studies, such as the FLOW trial on GLP-1 receptor agonists for kidney outcomes and the Surmount OSA study on sleep apnea, were discussed.

Dr. John Buse shared insights from the Catalyst Study, revealing a high prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes, potentially reshaping future screening and treatment guidelines.

  • 1yr
    Fascinating studies and gives us another armament to control DM, HTN ASVD , CKD hopefully in the near future thanks
  • Saved

1yr
Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand

Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand

Source : https://pubmed.ncbi.nlm.nih.gov/38542510/

Lipoprotein(a) [Lp(a)] consists of a low-density lipoprotein-like molecule and an apolipoprotein(a) [apo(a)] particle. Lp(a) has been suggested to be an independent risk factor of atherosclerotic cardiovascular disease (ASCVD). Lp(a) plasma...

The review highlights that while Lp(a) is a stable, genetically-determined risk factor for ASCVD, novel therapies like ASOs, siRNAs, and muvalaplin offer promising advancements in targeted treatment.

  • Saved

1yr
Cardiovascular Disease in Anti-neutrophil Cytoplasm Antibody-Associated Vasculitis

Cardiovascular Disease in Anti-neutrophil Cytoplasm Antibody-Associated Vasculitis

Source : https://pubmed.ncbi.nlm.nih.gov/38015334/

The incidence of cardiovascular disease in AAV exceeds that expected by traditional risk factors alone, suggesting a contribution from disease-specific factors. Similarly, it is unclear how different immunosuppressive therapies contribute...

Cardiovascular disease risk in AAV surpasses traditional factors, with disease-specific contributions and unclear effects of therapies. Improved risk assessment tools and cardioprotective strategies are needed for better long-term outcomes.